NSAIDs and cardiovascular risk | Semantic Scholar
ASK DIS: NSAIDS : Cardiovascular Risks
Diclofenac significantly increases cardiovascular risk, large study suggests | MIMS online
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Diclofenac Under Fire for Cardiovascular Risk | Docwire News
Diclofenac (Voltaren) and risk of cardiovascular events (heart attack and stroke)
Common painkiller linked to an increased risk of heart problems
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology
Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction - ScienceDirect
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
The Big Idea: the coxib crisis Iron, aspirin and heart disease risk revisited - Jerome L Sullivan, 2007
PDF) Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis
Diclofenac sodium vs Voltaren | Power
Cardiovascular effects and safety of (non-aspirin) NSAIDs | Nature Reviews Cardiology
Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries – topic of research paper in Economics and business.
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review | Advances in Therapy
NSAIDs: Medicines involved | Medicines Safety Portal
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Diclofenac (Voltaren) and risk of cardiovascular events (heart attack and stroke)
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet
